What Every Woman Should Know about Cervical Cancer : (Record no. 121379)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 11336nam a22005053i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC4772354 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240729131013.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2016 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9789401775601 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9789401775595 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC4772354 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL4772354 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (CaPaEBR)ebr11319758 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (CaONFJC)MIL984441 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)967528549 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RC261-271 |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.9946606 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Markovic, Nenad. |
| 245 10 - TITLE STATEMENT | |
| Title | What Every Woman Should Know about Cervical Cancer : |
| Remainder of title | Revised and Updated. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 2nd ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Dordrecht : |
| Name of producer, publisher, distributor, manufacturer | Springer Netherlands, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2016. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2016. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (553 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Intro -- To Our Family -- Message from the Authors -- Foreword to the 2016 Edition -- Between Two Editions -- Tribute to the Readers and the Followers of Our Work -- About the Book and the Authors -- The New Edition -- Readers Testimonials -- Afterword to 2008 Edition -- Acknowledgment -- Contents -- Introduction 2016 -- Chapter 1: The Female Reproductive System in Health and Disease -- 1.1 Basic Anatomy of the Female Reproductive System -- 1.1.1 The Ovaries -- 1.1.2 Fallopian Tubes -- 1.1.3 The Uterus -- 1.1.4 The Vagina -- 1.1.5 The Vulva and the Perineum -- 1.2 Basic Physiology of the Female Reproductive System -- 1.2.1 Female Hormones -- 1.2.2 The Menstrual Cycle -- 1.2.3 Pregnancy -- 1.2.4 Menopause -- 1.3 An Overview of the Most Common Women's Diseases -- 1.3.1 Menstrual Disorders -- 1.3.1.1 Amenorrhea -- 1.3.1.2 Dysmenorrhea -- 1.3.1.3 Abnormal Uterine Bleeding -- 1.3.1.4 Premenstrual Syndrome (PMS) -- 1.3.2 Other Disorders -- 1.3.2.1 Infertility -- 1.3.3 Common Infections in Women -- 1.3.3.1 Candida (Yeast) Vaginal Infections -- 1.3.3.2 Vaginitis and Vaginosis -- 1.3.3.3 Cervicitis -- 1.3.3.4 Nabothian Cyst -- 1.3.3.5 Pelvic Inflammatory Disease (PID) -- 1.3.4 Sexually Transmitted Diseases -- 1.3.4.1 Gonorrhea -- 1.3.4.2 Chlamydial Infection -- 1.3.4.3 Trichomoniasis -- 1.3.4.4 Herpetic Lesions of the Vulva, Vagina and Cervix -- 1.3.4.5 Human Papilloma Virus (HPV) Infection: Genital Warts -- 1.3.4.6 Acquired Immunodeficiency Syndrome (HIV, Aids) -- 1.3.4.7 Syphilis -- 1.4 Tumors of the Female Genital System -- 1.4.1 Benign Tumors -- 1.4.1.1 Myoma (Fibroid, Fibromyoma) -- 1.4.1.2 Cervical and Uterine Polyps -- 1.4.1.3 Endometriosis -- 1.4.2 Malignant Tumors Other than Cervical Cancer -- 1.4.2.1 Uterine Cancer -- 1.4.2.2 Ovarian Tumors -- 1.4.2.3 Carcinoma of the Vagina and Vulva -- Chapter 2: Cervical Cancer. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 2.1 About Cervical Cancer and Pre-cancerosis in This Book -- 2.1.1 Introduction -- 2.1.2 Definition -- 2.1.3 Interpretation -- 2.1.3.1 How to Approach These Issues from a Lay Person Perspective -- 2.1.3.2 Caution -- 2.2 Epidemiology of Cervical Cancer -- 2.3 Prevention and Control of Cervical Cancer -- 2.3.1 Risk Factors and Education to Reduce Their Influence -- 2.3.1.1 Human Papilloma Virus (Genital Warts) -- 2.3.1.2 Human Immunodeficiency Virus (HIV) Infection - AIDS -- 2.3.1.3 Smoking -- 2.3.1.4 Chlamydia Infection (Lymphogranuloma Venerum) -- 2.3.1.5 Diet and Cervical Cancer -- 2.3.1.6 Oral Contraceptives and Cervical Cancer -- 2.3.1.7 Multiple Pregnancies -- 2.3.1.8 Low Socioeconomic Status -- 2.3.1.9 DES - Diethylstilbestrol -- 2.3.1.10 Family History of Cervical Cancer -- 2.3.1.11 Other Sexually Transmitted Diseases -- 2.3.1.12 General Cancer Related Risk Factors -- 2.3.1.13 Absenteeism from Pap Test Screening. False Negative Pap Test -- 2.3.2 Cancer Control: Cervical Cancer/Pre-cancerosis Screening -- 2.3.2.1 Pap Test or Cytology-Based Cervical Cancer Screening -- Overview -- History -- Questions and Answers About Your Pap Test -- Frequency -- What Type of Screening? -- What Type of Specimen Collection? -- Why Waiting for Pap Test Result Is so Long? -- What to Expect from the Pap Test Result? -- What if Disease Is Present? -- Problem. Why Some Women Do not Take a Simple Pap Test and Get a Deadly Disease? -- 2.3.2.2 MarkPap Technology for Cervical Cancer Screening. What Is this? -- Why Should Women Know About this Emerging Technology? -- 2.3.3 Non Cytology-Based Cervical Cancer Screening -- 2.3.3.1 Instead of Conclusion -- 2.3.4 Management of Women When the Pap Test Result Returns -- 2.3.4.1 Pap Test Negative -- 2.3.4.2 Positive Pap Test -- 2.3.4.3 What to Do? -- 2.3.4.4 Points to Consider -- 2.3.5 Biomarkers and Cervical Cancer. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 2.3.5.1 Biomarkers as Analyte-Specific Reagents (ASR) -- 2.3.5.2 Cytological Biomarkers -- 2.3.5.3 MarkPap Test a Biomarker or a Surrogate End-Point for Colposcopy -- 2.3.5.4 PAP Smear as a Biomarker for Colposcopy Versus MarkPap Test -- 2.3.6 Human Papilloma Virus and Cervical Cancer -- 2.3.6.1 HPV Disease -- 2.3.6.2 HPV Prevention and Vaccines -- HPV Vaccines -- Tomorrow -- 2.4 Diagnosis and Treatment of Cervical Cancer -- 2.4.1 Diagnostic Methods -- 2.4.1.1 Anamnesis - History -- 2.4.1.2 Pelvic Exam -- 2.4.1.3 Colposcopy -- 2.4.1.4 Biopsy -- 2.4.1.5 Histology -- 2.4.1.6 Ancillary Methods -- 2.4.1.7 Diagnostic Interventions -- Loop Excision -- Cone Biopsy -- 2.4.2 Staging System -- 2.4.2.1 Medical Imaging Used for Staging Cervical Cancer -- 2.4.3 Planning Therapy -- 2.4.4 Cervical Cancer Treatment -- 2.4.4.1 Surgical Therapy -- Hysterectomy -- 2.4.4.2 Radiotherapy of Cervical Cancer -- 2.4.4.3 Chemotherapy of Cervical Cancer -- 2.4.4.4 Non-surgical Therapy -- Therapeutic Vaccination -- Self-Support -- 2.4.4.5 Immunotherapy -- 2.5 2016 Estimate of the Prognosis for Cervical Cancer -- Chapter 3: Coping and Living with Cervical Cancer -- 3.1 Coping -- 3.1.1 How to Cope When the Result Is Abnormal Pap Test? -- 3.1.2 The Diagnosis Is Cervical Cancer -- 3.1.3 Support from Caregivers and Close Family in Day-by-Day Coping with the Disease -- 3.1.4 Support of Extended Family and Friends -- 3.1.5 Support Groups -- 3.2 Living with Cancer -- 3.2.1 Complementary and Alternative Medicine -- 3.2.2 Holistic View of Health and Wellness -- 3.2.3 Which Are Other Dimensions of Health Described as a Holistic Health Model? -- 3.2.4 How We Can Achieve a Higher Level of Wellness Across all Dimensions of Health? -- 3.2.5 Understanding the Mechanism of Stress -- 3.2.6 Stress Release Strategies -- 3.2.6.1 Rethink -- 3.2.6.2 Reduce -- 3.2.6.3 Relaxation Techniques. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Passive Relaxation Techniques -- Active Relaxation Strategies -- 3.2.6.4 Reorganize - The Last Step: Use all the Resources to Become a More Stress-Resistant Person -- 3.2.7 An Overview on Eating for Optimal Health in Cancer Prevention and Cervical Cancer -- 3.3 Stories from Real People -- 3.4 Survey on What Women Think About Pap Test -- 3.4.1 Background -- 3.4.2 Identifying the Problem -- 3.4.3 Addressing the Problem - Study -- 3.4.4 Study Results and Analysis -- 3.4.5 Conclusion -- 3.4.6 Post Survey -- Chapter 4: Cervical Cancer Screening After 2008 -- 4.1 Current Practices -- 4.1.1 Afterword to 2008 Edition -- 4.1.2 What Happened with Pap Test After 2008 -- 4.1.2.1 Dethroning the Classic Pap test -- 4.1.2.2 Disappointment with the Global Outreach -- 4.1.2.3 Failure of Alternatives to Repeat the Success Results of Pap Test in the US -- 4.1.2.4 Attempts to Balance the Screening Cost with the Benefits Obtained -- 4.1.2.5 Search for New Ideas to Reverse the Increasing Cervical Cancer Trends Worldwide -- 4.1.2.6 Change of WHO Strategy -- 4.1.3 Pap Test Now -- 4.1.4 Challenges to Standard Pap Test After 2008 -- 4.1.4.1 Overview -- 4.1.4.2 A Meaningful Composite Biomarker -- 4.1.4.3 Automatic Screening - Image Analysis -- 4.1.4.4 Outreach -- 4.1.4.5 Screening with Biomarker -- 4.1.4.6 Funding Cervical Cancer Control -- 4.1.5 Pap Smear Test Vs Liquid-Based Pap Test -- 4.1.6 HPV Testing and Immunization -- 4.1.6.1 Co-testing HPV + Cytology Improved by CAP-PAP Test -- 4.1.6.2 Immunization -- 4.1.7 Management of Women After Pap Test -- 4.1.7.1 Background -- 4.1.7.2 Critical Reading -- 4.2 Guidelines -- 4.2.1 Overview of Guidelines After 2008 -- 4.2.2 Individual Guidelines -- 4.2.2.1 ACOG -- 4.2.2.2 ASC 2015 -- 4.2.2.3 ASCCP -- 4.2.2.4 USPSTF -- 4.2.2.5 WHO -- 4.2.2.6 2012 TBS Updates -- Chapter 5: Global Cervical Cancer Screening. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 5.1 Worldwide Application of Cervical Cancer Screening -- 5.2 Cervical Cancer Statistics - World -- 5.3 Preliminary Data on World Population: Health Demography -- 5.4 Cancer in the World -- 5.4.1 Continents - World Summary -- 5.4.1.1 Overview - Cervical Cancer in the World -- 5.4.2 Examples from Individual Countries -- 5.4.2.1 Cervical Cancer in the World -- 5.5 Gross Domestic Product - World -- 5.6 Study Summary: The Vision -- 5.7 New Avenues -- 5.7.1 US-India Symposium on Cervical Cancer -- 5.7.1.1 Cervical Cancer in India -- Problem for Indian Healthcare Providers -- How This Problem Was Solved in the US -- Indian Awareness of the Problem -- Symposium Impact: New Strategy -- New Tools for New Strategy: Information Technology, Digital Health -- Classic Medicine Must Adjust Old Canons to Allow New Technology to Be Safe and Effective -- Biomarkers Are Bridges Between Classic and Digital Medicine -- Education Is Still the Moving Power -- 5.7.2 India Press Release 2015 -- 5.7.3 Cervical Cancer in China Press Release 2015 -- 5.7.4 NIH Grant Proposal: Mobile Telecytopathology (Model: Republic of Serbia) -- 5.7.4.1 Republic of Serbia -- Cervical Cancer in Serbia -- Klinicko-Bolnicki Centar Zemun - Beograd -- Specific Research Interest of the Participating Institutes and Centers -- Post Grant Maintenance of Infrastructure and Services - Sustain the Social Impact by Self-Sustaining Financial Growth -- Chapter 6: New Strategy and Its Global Application -- 6.1 Executive Summary -- 6.2 Global Cervical Cancer Screening -- 6.2.1 New Strategy for Fighting Cervical Cancer Globally -- 6.2.1.1 Introduction -- Why New Strategy? -- Which Strategy to Choose for Cervical Cancer Screening? -- New Strategy (Applied for India) -- How to fund new strategy? -- Instead of Conclusion -- 6.3 MarkPap Technology Platform -- 6.3.1 MarkPap Advantage. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 6.4 Social Impact: Alleviating Health Disparities in Low-Middle-Income-Countries (LMIC). |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Family medicine. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Markovic, Olivera. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Markovic, Nenad |
| Title | What Every Woman Should Know about Cervical Cancer |
| Place, publisher, and date of publication | Dordrecht : Springer Netherlands,c2016 |
| International Standard Book Number | 9789401775595 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=4772354">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=4772354</a> |
| Public note | Click to View |
No items available.